The therapeutic effect of Favipiravir in COVID-19 patients

Phase 3

Recruiting

Conditions: COVID-19.
COVID-19 has been confirmed by laboratory testing irrespective of severity of clinical signs or symptoms
U07.1

Registration Number: IRCT20211004052664N1

Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 80

Inclusion Criteria

Laboratory covfirmation of COVID-19 virus by RT-PCR or imaging findings consistent with COVID-19
Moderate-severity disease (respiratory rate <30 per minute, oxygen saturation > 94% or pulmonaru infiltration < 50% in both lungs)
Age above 14 years
Willingness to participate in this study

Exclusion Criteria

Immunocompromised patients
Pregnancy
Consumption of effective drugs in the treatment of COVID-19 in this clinical course
History of severe hypersensitivity or anaphylactic shock

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Body temperature. Timepoint: Days 1 (start of treatment), 3, 5 and 7. Method of measurement: Thermometer.;Respiratory rate (per minute). Timepoint: Days 1 (start of treatment), 3, 5 and 7. Method of measurement: Physical examination by physician.;Oxygen saturation. Timepoint: Days 1 (start of treatment), 3, 5 and 7. Method of measurement: Pulseoxymeter.

Secondary Outcome Measures

Name	Time	Method
Hospitalization. Timepoint: Seventh day from the beginning of treatment. Method of measurement: Patient medical record.;Serum CRP level. Timepoint: Days 1 (start of treatment), 3, 5, and 7. Method of measurement: Laboratory report.;Lymphocyte count. Timepoint: Days 1 (start of treatment), 3, 5, and 7. Method of measurement: Laboratory report.